Literature DB >> 2887552

Behavioral toxicity of antipsychotic drugs.

T Van Putten, S R Marder.   

Abstract

Extrapyramidal symptoms cause much misery, often go undiagnosed, and can interfere with treatment and rehabilitation. Akinesia is a behavioral state of diminished motoric and psychic spontaneity that is difficult to distinguish from the negative symptoms of schizophrenia. The most useful clinical correlates of akinesia are a subjective sense of sedation and excessive sleeping. Akinesia interferes with social adjustment and may manifest as "postpsychotic depression." The subjective restlessness of akathisia is usually accompanied by telltale foot movements: rocking from foot to foot while standing or walking on the spot. Akathisia is strongly associated with depression and dysphoric responses to neuroleptics and has even been linked to suicidal and homicidal behavior in extreme cases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887552

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

3.  Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs.

Authors:  Emanuela Offidani; Giovanni A Fava; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

4.  Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity.

Authors:  Marc-André Roy; Marie-France Demers; Amélie M Achim
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  Akathisia following traumatic brain injury: treatment with bromocriptine.

Authors:  J T Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-10       Impact factor: 10.154

7.  Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year "open" follow-up study.

Authors:  Giulio Perugi; Franco Frare; Cristina Toni; Giuseppe Tusini; Giulia Vannucchi; Hagop S Akiskal
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-03-18       Impact factor: 5.270

8.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

9.  A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen; Yuki Takahashi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 10.  Drug-induced depression in the aged. What can be done?

Authors:  L Ganzini; J R Walsh; S B Millar
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.